Amygdala Neurosciences Overview
- Founded
- 2015
- Status
- Private
- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $5.6M
- Investors
- 2
Amygdala Neurosciences General Information
Description
Operator of a biopharmaceutical firm intended to focus on the large and growing unmet need associated with substance use disorders. The company's firm uses a selective ALDH2 inhibitor that prevents a surge in dopamine levels and associated craving without changes to basal dopamine, enabling patients to quit and get rid of the addiction to drugs, alcohol, and smoking.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
- 5214F Diamond Heights Boulevard
- Suite 151
- San Francisco, CA 94131
- United States
+1 (650) 000-0000
Amygdala Neurosciences Timeline
Amygdala Neurosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Early Stage VC | 02-Nov-2019 | $5.6M | 000.00 | Completed | Generating Revenue | |
| 5. Grant | 21-Oct-2019 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 4. Grant | 19-Sep-2018 | 000.00 | 00.000 | Completed | Generating Revenue | |
| 3. Seed Round | 19-May-2017 | 00.000 | 00.000 | 000.00 | Completed | Generating Revenue |
| 2. Seed Round | 10-Feb-2017 | $2M | $3.45M | 000.00 | Completed | Generating Revenue |
| 1. Seed Round | 10-Apr-2015 | $1.45M | $1.45M | 000 | Completed | Generating Revenue |
Amygdala Neurosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-3 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Seed-2 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Seed-1 | 5,307,464 | $0.000100 | $0.02 | $0.27 | $0.27 | 1x | $0.27 | 25.3% |
Amygdala Neurosciences Executive Team (6)
Amygdala Neurosciences Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Howard Jaffe | Amygdala Neurosciences | Board Member | 000 0000 |
| Ivan Diamond Ph.D | Amygdala Neurosciences | Co-Founder, Board Member & Chief Scientific Officer | 000 0000 |
| Louis Lange MD | Amygdala Neurosciences | Co-Founder & Chairman | 000 0000 |
| Mack Mitchell MD | Self | Chief Medical Officer & Board Member | 000 0000 |
| Peter Strumph | Amygdala Neurosciences | Co-Founder, President, Chief Executive Officer and Board Member | 000 0000 |
Amygdala Neurosciences Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Asset Management Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| National Institutes of Health | Government | 000 0000 | 000000 0 |
Amygdala Neurosciences Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 00000000 (0 | 16-Feb-2017 | 000000000 00000 00 | Buildings and Property | 00000 0000000 |